AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AngioDynamics, Inc.NASDAQ: ANGO
Accounts Receivables · Q3 FY2026 · quarter ended Feb 2026
Accounts receivables growth accelerates
Q3 FY2026 accounts receivables of $1.42M (cash outflow) rose 199.2% year over year, ahead of the -146.8% change in trailing-twelve-month accounts receivables. Sequentially, it fell 9.6% from the prior quarter.
Context
- Accounts receivables amounted to 0.0% of revenue in FY2025, down 2.6 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +199.2% holds above the trailing-twelve-month pace of -146.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 23K USD
- Year-over-year change
- -99.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | 23K | -99.7% |
| FY2024 | 2024-05-31 | 7.89M | +707.7% |
| FY2023 | 2023-05-31 | (1.3M) | +92.4% |
| FY2022 | 2022-05-31 | (17.15M) | -312.1% |
| FY2021 | 2021-05-31 | (4.16M) | — |
Accounts Receivables vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's LTM Feb 2026 accounts receivables of $2.4M is the 7th largest of the 9 companies compared; the peer median is $9.07M.
- Its year-over-year change of -146.8% is the 6th highest of 8, against a peer median of -84.7%.
- Accounts receivables amounts to 0.8% of revenue for ANGO, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $293M | +144.2% | +6.9% | 1.4% | |
| LTM Jun 2026 | $67.5M | +15.6% | +30.5% | 2.6% | |
| LTM Jun 2026 | $17.77M | -172.9% | -34.6% | 1.2% | |
| LTM Sep 2026 | $9.85M | -15.4% | -43.5% | 0.6% | |
| LTM Mar 2026 | $8.29M | -169.0% | -75.7% | 0.5% | |
| LTM Mar 2026 | $2.74M | -115.0% | -23.2% | 0.2% | |
| LTM Feb 2026 | $2.4M | -146.8% | — | 0.8% | |
| LTM Mar 2026 | $809K | -84.7% | -5.9% | 0.3% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANGO) | $9.07M | -84.7% | -23.2% | 0.6% | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Net Income | (31.55M) | (26.55M) | (52.44M) | (184.35M) | (33.99M) |
| Depreciation & Amortization | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M |
| Deferred Income Tax | (4.81M) | (3.71M) | (2.31M) | (7.97M) | (988K) |
| Stock-Based Compensation | 8.63M | 10.69M | 11.16M | 10.53M | 9.77M |
| Change in Working Capital | 9.07M | (21.05M) | (7.03M) | 14.42M | (14.11M) |
| Accounts Receivables | (4.16M) | (17.15M) | (1.3M) | 7.89M | 23K |
| Inventory | 11.54M | (2.8M) | (8.2M) | (9.41M) | (1.35M) |
| Accounts Payables | 4.88M | 3.91M | 2.14M | 27.53M | (15.88M) |
| Other Working Capital | (3.18M) | (5.01M) | 332K | (11.59M) | 3.09M |
| Other Non-Cash Items | 16.83M | 4.07M | 19.83M | 111.5M | 3.39M |
| Operating Cash Flow | 24.09M | (7.19M) | 78K | (28.16M) | (10.13M) |
| Capital Expenditures | (5.19M) | (4.3M) | (4.35M) | (5.77M) | (4.46M) |
| Acquisitions (Net) | 0 | (3.6M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (8.52M) | (11.41M) | (5.93M) | 126.24M | (5.71M) |
| Investing Cash Flow | (13.71M) | (19.31M) | (9.75M) | 123.72M | (10.18M) |
| Debt Repayment | (20M) | 5M | 25M | (50M) | 6.16M |
| Common Stock Issued | 3.01M | 2.68M | 1.17M | 752K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (1.67M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (751K) | (15M) | (4.75M) |
| Financing Cash Flow | (16.99M) | 7.68M | 25.42M | (64.25M) | (255K) |
| Effect of Forex Changes | 330K | (518K) | 43K | 125K | 398K |
| Net Change in Cash | (6.27M) | (19.34M) | 15.8M | 31.44M | (20.16M) |
| Free Cash Flow | 18.91M | (11.49M) | (4.27M) | (33.93M) | (14.59M) |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.